HDAC inhibitors in liver cancer: which route to take?
Kiesslich, Tobias
HDAC inhibitors in liver cancer: which route to take? [electronic resource] - Expert review of gastroenterology & hepatology Jun 2019 - 515-517 p. digital
Publication Type: Editorial
1747-4132
10.1080/17474124.2019.1605289 doi
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Carcinoma, Hepatocellular--drug therapy
Clinical Decision-Making
Disease Progression
Epigenesis, Genetic--drug effects
Histone Deacetylase Inhibitors--adverse effects
Humans
Liver Neoplasms--drug therapy
Patient Selection
Treatment Outcome
HDAC inhibitors in liver cancer: which route to take? [electronic resource] - Expert review of gastroenterology & hepatology Jun 2019 - 515-517 p. digital
Publication Type: Editorial
1747-4132
10.1080/17474124.2019.1605289 doi
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Carcinoma, Hepatocellular--drug therapy
Clinical Decision-Making
Disease Progression
Epigenesis, Genetic--drug effects
Histone Deacetylase Inhibitors--adverse effects
Humans
Liver Neoplasms--drug therapy
Patient Selection
Treatment Outcome